Search Results
Search results for "Bristol-Myers Squibb"
Results found for "Bristol-Myers Squibb"
- đź“° GPCR Weekly News, May 22 to 28, 2023
Receptor Complexes Industry News Mavorixafor reduces infection rates among patients with WHIM syndrome Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients
- đź“° GPCR Weekly News, March 11 to 17, 2024
GPCR mayo controls midgut development in Drosophila Karuna Therapeutics announces that is now part of Bristol Myers Squibb GPCR Events, Meetings, and Webinars March 23 - 24, 2024 | Ligand Recognition and Molecular
- Dr. Ben Myers - Dr. GPCR Podcast
Ben Myers!
- đź“° GPCR Weekly News, January 30 to February 5, 2023
Industry News Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta
- Addex Therapeutics CEO Tim Dyer: There is a $4-bil market opportunity in dyskinesia
January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for
- đź“° GPCR Weekly Buzz: Exciting Schedule Shifts for Principles of Pharmacology I & II | August 12-18, 2024
This week's highlight includes congrats to: Madison Walker , Benjamin Myers , et al., for their research
- đź“° GPCR Weekly News, September 11 to 17, 2023
Ben Myers and Dr. Niña Caculitan.
- Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with ...
Applying Allosteric Modulator Pharmacology to Treat Dyskinesia and Other Movement Disorders with Tim Dyer Addex Therapeutics "Tim Dyer is the Co-Founder and CEO of Addex Therapeutics, which is focusing on the
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
Tim Dyer, CEO, Roger Mills, CMO and Robert LĂĽtjens, Head of Discovery Biology, will provide a business
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
strategic priorities, including pursuing additional collaborations across our portfolio,” said Tim Dyer
- đź“° GPCR Weekly News, November 6 to November 12, 2023
the present as prologue Industry News Exscientia Business Update for Third Quarter 2023 Addex CEO Tim Dyer
- Glyco-sulfo hotspots in the chemokine receptor system
which have an established role in chemokine gradients and oligomerization (Deshauer C et al. 2015; Dyer
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
.; Iyer, M. R.; Cinar, R.; Coffey, N.
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Rößler P, Mayer D, Tsai CJ, Veprintsev DB, Schertler GFX, Gossert AD.
